Mevrometostat
An epigenetic drug that may re-sensitise prostate cancer to hormone therapy, in three phase 3 trials with enzalutamide.
Phase 1/2: rPFS ~14 vs 6 months with enzalutamide vs enzalutamide alone after abiraterone. MEVPRO-1 (post-abiraterone mCRPC, open-label, n≈600, started Oct 2024, completion ~2028), MEVPRO-2 (double-blind), and MEVPRO-3 (mCSPC, ASCO GU 2026 trial-in-progress). No approval yet.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Mevrometostat" OR ABSTRACT:"Mevrometostat" OR TITLE:"PF-06821497" OR ABSTRACT:"PF-06821497") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mevrometostat, not a curated reading list.